Claims
- 1. A peptide of SEQ ID NO: 1.
- 2. The peptide of claim 1, wherein said peptide is formed by a process comprising the steps of:
a. forming a mixture including a protein combination consisting of casein, beef peptone and bovine serum albumin, a plant RNA and a base in water, wherein the ratio of said protein combination to said water is in a range from about 1.5/100 to about 2.5/100 by weight; b. processing said mixture at an elevated temperature and an elevated pressure so as to form a solution and insoluble elements; c. removing said insoluble elements; d. diluting said solution with water; and e. after performing steps b, c and d, adjusting the pH of said solution to a physiologically acceptable pH.
- 3. The peptide of claim 1, wherein said peptide is chemically synthesized.
- 4. A nucleotide-peptide, comprising a peptide of SEQ ID NO: 2 and a nucleotide connected to said peptide, said nucleotide-peptide is represented by the following formula:
- 5. The nucleotide-peptide of claim 4, wherein said nucleotide-peptide is formed by a process comprising the steps of:
a. forming a mixture including a protein combination consisting of casein, beef peptone and bovine serum albumin, a plant RNA and a base in water, wherein the ratio of said protein combination to said water is in a range from about 1.5/100 to about 2.5/100 by weight; b. processing said mixture at an elevated temperature and an elevated pressure so as to form a solution and insoluble elements; c. removing said insoluble elements; d. diluting said solution with water; and e. after performing steps b, c and d, adjusting the pH of said solution to a physiologically acceptable pH.
- 6. The nucleotide-peptide of claim 4, wherein said nucleotide-peptide is chemically synthesized.
- 7. The nucleotide-peptide of claim 4, wherein said purine is selected from the group consisting of adenine, guanine, hypoxanthine, xantlnne and 6-mercaptopurine, said pyrimidine is selected from the group consisting of thymine, cytosine, 5-methylcytosine, 5-fluorouracil, 5-bromovinyluracil, 5-iodouracil, 2-fluoroadenine, 5-fluorocytosine, uracil.
- 8. The nucleotide-peptide of claim 1, wherein said oligo-nucleotide is covalently connected to a serine residue of said peptide at the hydroxyl group of said serine residue.
- 9. The nucleotide-peptide of claim 8, wherein said nucleotide is a dinucleotide.
- 10. The nucleotide-peptide of claim 9, wherein said dinucleotide is a diadenosine.
- 11. The nucleotide-peptide of claim 10, wherein said diadenosine is connected to said serine residue through a diphosphodiester linkage.
- 12. The nucleotide-peptide of claim 11, wherein said serine residue is number 18 amino acid residue from the N-terminal of said peptide.
- 13. A nucleotide-peptide, comprising a peptide having a hydroxylated amino acid residue, and a nucleotide having a diphosphodiester moiety, wherein said peptide is covalently connected to said nucleotide at the hydroxyl group of said hydroxylated amino acid residue through said diphophodiester.
- 14. The nucleotide-peptide of claim 13, wherein said nucleotide is a dinucleotide.
- 15. The nucleotide-peptide of claim 13, wherein said nucleotide is selected from the group consisting of adenine, guanine, hypoxanthine, xanthine, uracil thymine, cytosine, 5-methylcytosine, 5-fluorouracil, 5-bromovinyluracil, 5-iodouracil, 2-fluoroadenine, 5-fluorocytosine, 6-mercaptopurine.
- 16. The nucleotide-peptide of claim 13, wherein said hydroxylated amino acid is selected from the group consisting of serine, threonine and tyrosine.
- 17. A pharmaceutical composition, comprising a peptide of SEQ ID NO: 1.
- 18. A pharmaceutical composition, comprising a nucleotide-peptide, said nucleotide-peptide comprising a peptide having a serine residue, and a nucleotide having a diphosphodiester moiety, wherein said peptide is covalently connected to said nucleotide at the hydroxyl group of said serine residue through said diphophodiester.
- 19. The pharmaceutical composition of claim 18, further comprising a peptide of SEQ ID NO: 1.
- 20. A pharmaceutical composition, comprising a nucteotide-peptide which comprises a peptide of SEQ ID NO: 2 and a nucleotide connected to said peptide, said nucleotide-peptide is represented by the following formula:
- 21. The nucleotide-peptide of claim 20, wherein said purine is selected from the group consisting of adenine, guanine, hypoxanthine, xanthine and 6-mercaptopurine, said pyrimidine is selected from the group consisting of thymine, cytosine, 5-methylcytosine, 5-fluorouracil, 5-bromovinyluracil, 5-iodouracil, 2-fluoroadenine, 5-fluorocytosine, uracil.
- 22. The nucleotide-peptide of claim 21, wherein said nucleotide is covalently connected to a serine residue of said peptide at the hydroxyl group of said serine residue.
- 23. The nucleotide-peptide of claim 22, wherein said nucleotide is a dinucleotide.
- 24. The nucleotide-peptide of claim 23, wherein said dinucleotide is a diadenosine.
- 25. The nucleotide-peptide of claim 24, wherein said diadenosine is connected to said serine residue through a diphosphodiester linkage.
- 26. The nucleotide-peptide of claim 10, wherein said serine residue is number 18 amino acid residue from the N-terminal of said peptide.
- 27. The pharmaceutical composition of claim 20, further comprising a peptide of SEQ ID NO: 1.
- 28. A pharmaceutical composition, comprising a peptide having about 31 amino acids and being capable of stimulating the production of interlukin-8 in cultured cells.
- 29. A pharmaceutical composition, comprising a nticleotide-peptide having a serine residue and a dinucleotide moiety, said nucleotide-peptide residue being capable of stimulating the production of interlukin-8 in cultured cells.
- 30. The pharmaceutical composition of claim 29, further comprising the peptide of claim 28.
- 31. A pharmaceutical composition, comprising a peptide having about 31 amino acids and being capable of stimulating the production of monocyte chemotactic protien 1 in cultured cells.
- 32. A pharmaceutical composition, comprising nucleotide-peptide having a serine residue and a dinucleotide moiety, said nucleotide-peptide residue being capable of stimulating the production of interlukin-8 in cultured cells.
- 33. The pharmaceutical composition of claim 32, further comprising the peptide of claim 31.
- 34. A pharmaceutical composition, comprising a peptide nucleic acid preparation that absorbs light at wavelengths 230 nm, 260 nm and 280 nm so as to result in 260 nm/280 nm absorption ratio of about 1.998 and 260 nm/230 nm absorption ratio of about 1.359, comprising molecules of nucleotides resulting from a plant RNA and peptides resulting from a mixture of casein, beef peptone and bovine serum albumin, said molecules having non-uniformly distributed molecular weights.
- 35. The composition of claim 34, wherein said nucleotides comprises mono-nucleotides.
- 36. The composition of claim 34, wherein said molecules have non-uniformly distributed molecular weights in a range from zero to substantially not more than 14 KDa by silver staining.
- 37. The composition of claim 34, wherein said molecules have non-uniformly distributed molecular weights in a range from zero to substantially not more than 8 KDa by silver staining.
- 38. The composition of claim 34, wherein said molecules have substantial concentrations at molecular weights of substantially 5.2 KDa and 4.3 KDa by silver staining.
RELATED APPLICATIONS
[0001] This is a continuation-in-part of application Ser. No. 09/344,095, filed on Jun. 25, 1999, which is a continuation-in-part of application Ser. No. 08/735,236, filed on Oct. 22, 1996. This application incorporates the contents of the application Ser. Nos. 09/344,095 and 08/735,236 by reference in their entirety.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09764017 |
Jan 2001 |
US |
Child |
10201210 |
Jul 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09344095 |
Jun 1999 |
US |
Child |
09764017 |
Jan 2001 |
US |
Parent |
08735236 |
Oct 1996 |
US |
Child |
09344095 |
Jun 1999 |
US |